KS-133

Ac-c[Cys-Pro-Pro-Tyr-Leu-Pro-c(Lys-Tyr-Leu-Cys]-Asp)-Leu-Ile-NH2; Contains disulfide bond cyclization with side chains of Cys1 and Cys10, and amide bond cyclization with side chains of Lys7 and Asp11

Also Known As:

Networked: 3 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Ago, Yukio: 1 article (01/2021)
2.	Asano, Satoshi: 1 article (01/2021)
3.	Chen, Lu: 1 article (01/2021)
4.	Hino, Nobumasa: 1 article (01/2021)
5.	Ishimoto, Kenji: 1 article (01/2021)
6.	Masutani, Teruaki: 1 article (01/2021)
7.	Miyaoka, Tatsunori: 1 article (01/2021)
8.	Nakagawa, Shinsaku: 1 article (01/2021)
9.	Sakamoto, Kotaro: 1 article (01/2021)
10.	Yamada, Mei: 1 article (01/2021)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2023 - "A pharmacokinetic study suggested that the enhancement of anti-tumor activity was associated with improvement of the pharmacokinetic profile of KS-133 upon nanoformulation. " 01/01/2023 - "In this study, we aimed to examine whether the selective blockade of VIPR2 by KS-133 changes the polarization of macrophages and induces anti-tumor effects. " 01/01/2023 - "Subcutaneous administration of KS-133 NPs once every 3 days had stronger anti-tumor effects than daily subcutaneous administration of KS-133. " 01/01/2023 - "The VIPR2-selective antagonist KS-133 changes macrophage polarization and exerts potent anti-tumor effects as a single agent and in combination with an anti-PD-1 antibody." 01/01/2023 - "Daily subcutaneous administration of KS-133 tended to suppress the growth of CT26 tumors (murine colorectal cancer-derived cells) implanted subcutaneously in Balb/c mice. "
2.	Cognitive Dysfunction 05/01/2023 - "We have developed a bicyclic peptide KS-133, which shows VIPR2 antagonist activity and suppresses cognitive decline in a mouse model relevant to schizophrenia. " 01/01/2021 - "Generation of KS-133 as a Novel Bicyclic Peptide with a Potent and Selective VIPR2 Antagonist Activity that Counteracts Cognitive Decline in a Mouse Model of Psychiatric Disorders."
3.	Colorectal Neoplasms (Colorectal Cancer) 01/01/2023 - "Daily subcutaneous administration of KS-133 tended to suppress the growth of CT26 tumors (murine colorectal cancer-derived cells) implanted subcutaneously in Balb/c mice. "
4.	Schizophrenia (Dementia Praecox) 05/01/2023 - "We have developed a bicyclic peptide KS-133, which shows VIPR2 antagonist activity and suppresses cognitive decline in a mouse model relevant to schizophrenia. "
5.	Mental Disorders (Mental Disorder) 01/01/2021 - "After amino acid substitution and structure optimization, we successfully generated KS-133 with 1) a VIPR2-selective and potent antagonistic activity, 2) at least 24 h of stability in plasma, and 3) in vivo pharmacological efficacies in a mouse model of psychiatric disorders through early postnatal activation of VIPR2. " 01/01/2021 - "Generation of KS-133 as a Novel Bicyclic Peptide with a Potent and Selective VIPR2 Antagonist Activity that Counteracts Cognitive Decline in a Mouse Model of Psychiatric Disorders."

Related Drugs and Biologics

1.	Peptides (Polypeptides)
2.	Genetic Markers (Genetic Marker)
3.	Immune Checkpoint Inhibitors